HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

Abstract
Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S proteasome, may affect proteasome function, assembly, and/or binding of proteasome inhibitors. To investigate the potential association between PSMB gene variants and treatment-emergent resistance to bortezomib and/or long-term outcomes, in the present study, PSMB gene sequence variation was characterized in tumor DNA samples from patients who participated in the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib versus high-dose dexamethasone for treatment of relapsed multiple myeloma. Twelve new PSMB variants were identified. No associations were found between PSMB single nucleotide polymorphism genotype frequency and clinical response to bortezomib or dexamethasone treatment or between PSMB single nucleotide polymorphism allelic frequency and pooled overall survival or time to progression. Although specific PSMB5 variants have been identified previously in preclinical models of bortezomib resistance, these variants were not detected in patient tumor samples collected after clinical relapse from bortezomib, which suggests that alternative mechanisms underlie bortezomib insensitivity.
AuthorsDavid I Lichter, Hadi Danaee, Michael D Pickard, Olga Tayber, Michael Sintchak, Hongliang Shi, Paul G Richardson, Jamie Cavenagh, Joan Bladé, Thierry Façon, Ruben Niesvizky, Melissa Alsina, William Dalton, Pieter Sonneveld, Sagar Lonial, Helgi van de Velde, Deborah Ricci, Dixie-Lee Esseltine, William L Trepicchio, George Mulligan, Kenneth C Anderson
JournalBlood (Blood) Vol. 120 Issue 23 Pg. 4513-6 (Nov 29 2012) ISSN: 1528-0020 [Electronic] United States
PMID23018640 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Protein Subunits
  • Pyrazines
  • LMP-2 protein
  • Bortezomib
  • Dexamethasone
  • Cysteine Endopeptidases
  • LMP7 protein
  • PSMB1 protein, human
  • PSMB10 protein, human
  • PSMB5 protein, human
  • PSMB6 protein, human
  • Proteasome Endopeptidase Complex
Topics
  • Antineoplastic Agents (therapeutic use)
  • Boronic Acids (therapeutic use)
  • Bortezomib
  • Cysteine Endopeptidases
  • Dexamethasone (therapeutic use)
  • Drug Resistance, Neoplasm (genetics)
  • Gene Frequency
  • Genotype
  • Humans
  • Multiple Myeloma (drug therapy, genetics, pathology)
  • Polymorphism, Single Nucleotide
  • Proteasome Endopeptidase Complex (genetics)
  • Protein Subunits (genetics)
  • Pyrazines (therapeutic use)
  • Recurrence
  • Sequence Analysis, DNA
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: